Stifel Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $49
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Alex Thompson has initiated coverage on Oruka Therapeutics with a Buy rating and set a price target of $49.
October 11, 2024 | 9:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel has initiated coverage on Oruka Therapeutics with a Buy rating and a price target of $49, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $49 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100